Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
Eastern Cooperative Oncology Group
Kaiser Permanente
Washington University School of Medicine
City of Hope Medical Center
University of Nebraska
Eli Lilly and Company
Var2 Pharmaceuticals
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Travera Inc
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Turning Point Therapeutics, Inc.
Eli Lilly and Company
Tempus AI
Institut du Cancer de Montpellier - Val d'Aurelle
Stanford University
Intensity Therapeutics, Inc.
Mayo Clinic
Rutgers, The State University of New Jersey
Stanford University
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
pharmaand GmbH
Kineta Inc.
Aesculap AG
Case Comprehensive Cancer Center
Genzada Pharmaceuticals USA, Inc.
Roswell Park Cancer Institute
MacroGenics
SpeciCare
Stanford University
Swiss Cancer Institute
CureOne
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MedInnovation GmbH
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Mayo Clinic
National Cancer Institute (NCI)
Altor BioScience
Stanford University
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center